<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11862439</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.1312</article-id><article-id pub-id-type="other">EPV0660</article-id><article-id pub-id-type="pii">S0924933824013129</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Viewing</subject></subj-group></article-categories><title-group><article-title>Alzheimer&#x02019;s and Parkinson&#x02019;s disease drugs side effects</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Batistela</surname><given-names>J.</given-names></name><xref rid="aff2922" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ropero Pelaez</surname><given-names>F. J.</given-names></name><xref rid="aff2923" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hida</surname><given-names>G.</given-names></name><xref rid="aff2924" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Taniguchi</surname><given-names>S.</given-names></name><xref rid="aff2925" ref-type="aff">
<sup>4</sup>
</xref><xref rid="cor1164" ref-type="corresp">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="aff2922"><sup>1</sup><institution>Albert Einstein Hospital</institution>, <city>S&#x000e3;o Paulo</city></aff><aff id="aff2923"><sup>2</sup>Mathematics, Computation and Cognition, <institution>University Federal of ABC</institution>, <city>Sao Paulo</city></aff><aff id="aff2924"><sup>3</sup>Big Data Analytics - Artificial Intelligence, <institution>Albert Einstein Hospital</institution></aff><aff id="aff2925"><sup>4</sup><institution>S&#x000e3;o Paulo University</institution>, <city>S&#x000e3;o Paulo</city>, <country>Brazil</country></aff><author-notes><corresp id="cor1164"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="1287">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S633</fpage><lpage>S634</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824013129a.pdf"/><abstract><sec id="sec6997"><title>Introduction</title><p>Alzheimer&#x02019;s and Parkinson&#x02019;s disease are neurodegenerative disorders with life limiting conditions. The symptomatic pharmacological therapeutic strategies unfortunately are also related to undesirable side effects. Acetylcholinesterase inhibitors administered to Alzheimer&#x02019;s disease patients increase cholinergic transmission in cortex and hippocampus.</p><p>Antiparkinsonian drugs increase dopaminergic system activity, to compensate for dopaminergic neurons&#x02019; degeneration in&#x000a0;<italic toggle="yes">corpus striatum, t</italic>herefore supplying the imbalance of these neurotransmitters in these degenerative areas.But&#x000a0;undesirable the increase of these neurotransmitters in other cerebral and peripheral areas brings us important side effects</p></sec><sec id="sec6998"><title>Objectives</title><p>To study Alzheimer&#x02019;s cholinergic drugs&#x000a0;and Parkinson&#x02019;s dopaminergic drugs&#x02019; side effects</p></sec><sec id="sec6999"><title>Methods</title><p>
This retrospective study included 107 geriatric patients enrolled in a private long-term care institution. 79 patients with Alzheimer&#x02019;s disease had mean age of 88.11 &#x000b1; 5,78 years old, mean weight of 61.62 &#x000b1; 13.10 kg. 28 patients with Parkinson&#x02019;s disease had mean age of&#x000a0;84.93 &#x000b1; 5.71 years old, weight mean 66.36 &#x000b1; 2.83 kg.</p></sec><sec id="sec7000"><title>Results</title><p>Alzheimer&#x02019;s disease patients&#x000a0;41.77% (33) received. Acetylcholinesterase inhibitors&#x000a0;(Donepezil, galantamine and rivastigmine) Psychomotor agitation and aggressive behavior 63.666% and nausea (15%) were observed in the patients treated with these drugs. The association of L-DOPA and DOPA decarboxylase inhibitors (benserazide) were administered to 53%(15) of the Parkinson&#x02019;s disease patients in doses between 2.0-19.0 mg/kg/day. L-DOPA associated to catechol-O-methyltransferase inhibitor (entacapone) 3 mg/kg/day were given to 7.14% (2) patients. Bromocriptine 0.04 mg/kg/day was given to 3.57% (1) patients. Mental confusion and hallucination side effects were observed in 53.33% (8) patients treated with L-DOPA associated with the DOPA decarboxylase inhibitor (benserazide).</p></sec><sec id="sec7001"><title>Conclusions</title><p>The increase of cholinergic activity due to the acetylcholinesterase inhibitors in the Nigro- striatal pathway could be related to psychomotor agitation in Alzheimer&#x02019;s disease patients in a similar way to akathisia induced by neuroleptics.&#x000a0;The increase of dopamine levels due to the administration of L-DOPA, in&#x000a0;<italic toggle="yes">corpus striatum</italic>&#x000a0;improved Parkinson&#x02019;s disease symptoms although the increase of dopaminergic activity at mesocortical pathways may be related to confusion and hallucination observed in these patients.&#x000a0;Adjustments in dosage of these drugs could provide improvement in these patients&#x02019; daily life conditions.</p></sec><sec id="sec7002"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>